Microbix announces extension of agreement with major vaccine producer
The initial evaluation period was to expire June 30, 2005. Microbix' partner has now been granted an additional 90-day period to continue testing the technology.
"During this extension, the Company and its partner will also be negotiating the final terms of the definitive licensing agreement," said William J. Gastle, President and CEO. Should the companies enter into a definitive licensing agreement, Microbix will receive milestone payments and royalties on worldwide sales of product using Microbix' technology.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.